Quality documentation · Batch review

Semaglutide API Documentation: Batch and Specification Review

Review a Semaglutide API documentation package by checking whether its records describe the same proposed material, the same batch and the same agreed requirements.

Start with document identity and version control, then assign unresolved questions to the appropriate technical or quality owner.

A folder containing every requested PDF is not necessarily a coherent package.

Published: Sep 24, 2026
Updated: Sep 24, 2026
By: LUMIRABIO Editorial Team
Reading time: 6 min read

Decision brief

Key Takeaways

Reconcile document revisions, not filenames alone.
Different sample, batch and shipment IDs need documented links.
Document reconciliation is not supplier approval or batch release.

1. Define the decision before requesting documents

An initial feasibility discussion and acceptance of a delivery are different decisions. For the first, a controlled specification proposal and a description of available evidence may be useful. For the second, reviewers need records connected to the actual supplied material. Do not treat an example document supplied during an introduction as evidence for a later shipment.

Write a short review brief containing the material description, intended institutional use, project stage, destination market and decision being requested. Identify who can resolve analytical questions, document discrepancies and supply-chain questions. Keep confidential process details out of an initial public inquiry.

For Semaglutide project discussions, distinguish the molecule name from the specific proposed form, grade and specification. A familiar name on a quotation does not settle those details. It also does not establish that the material is equivalent to a finished medicine or eligible for every market.

2. Build a document cross-reference, not just a file list

2. Build a document cross-reference, not just a file list
Record	Connection to verify	Question to resolve
Material description	Quotation and agreed specification	Are the proposed form and grade consistent?
Specification	Approved version and relevant methods	Which version governs this review?
Certificate of analysis (CoA)	Material identifier and manufacturer batch	Does it concern the actual proposed lot?
Laboratory report	Sample identifier and method reference	How was the submitted sample linked to that lot?
Packaging or delivery record	Container labels and shipment references	Can the received material be reconciled with the records?
Responsibility agreement	Parties, operations and contacts	Who answers discrepancies and communicates changes?

Use this table as a working review aid. These are suggested coordination fields, not a universal regulatory template. Record the document identifier and revision alongside its filename; filenames can change when documents move between email, portals and shared folders.

The practical output is a short discrepancy list with an owner and a next action for each item. A blank field should remain visibly unresolved. Do not replace an unknown manufacturer or missing version with an assumption simply to complete the spreadsheet.

3. Separate the specification from the batch result

A specification describes the requirements being applied; a certificate of analysis (CoA) reports results for an identified batch. Check the relationship between them rather than comparing only a headline percentage. FDA's Q7 guidance, within its scope, addresses batch identification, release information, test requirements, limits, results and manufacturer information in certificates of analysis. [1]

For your review worksheet, put the specification revision next to the certificate reference. If revisions differ, ask the document owner which requirements applied and whether a documented assessment is needed. A newer document is not automatically the right document for every historical batch. Equally, an older certificate should not be silently relabelled as meeting revised requirements.

Record method identifiers and reporting units exactly as supplied, then compare them with the applicable specification. Where a result needs analytical interpretation, refer it to the technical reviewer rather than relying on a commercial summary or an informal assumption. Our peptide impurity-control overview discusses how analytical questions connect to a broader control strategy; this article focuses on keeping the supporting records aligned.

4. Keep sample, batch and shipment identities distinct

A sample code, manufacturer lot and delivery reference may legitimately differ. The issue is whether a controlled record explains their relationship. Ask for that link instead of requiring every identifier to be identical or assuming different identifiers prove a quality failure.

Consider a hypothetical case: the quotation lists one product code, the laboratory uses an internal sample number, and the delivery label carries a distributor reference. None of those labels alone shows which manufacturer lot was tested. A reconciliation record could clarify the relationship, while any remaining gap should be assessed before the intended decision. This example is not a report of an actual LUMIRABIO shipment.

Also ask whether the reviewed sample and the proposed supply share a supported relationship. A favourable result on an introductory sample is not, by itself, evidence about every later lot. Sampling and interpretation belong with the responsible quality and analytical teams. Do not turn document matching into a substitute for their assessment.

5. Give discrepancies an owner and an escalation route

The seller, manufacturer, laboratory and logistics provider can have different roles. A useful package identifies the relevant party for each question without implying that one contact performs every operation. Request a clear route for resolving missing records, changed requirements and inconsistent identifiers.

FDA's guidance on contract manufacturing quality agreements explains how relevant manufacturing activities and responsibilities can be documented. It also makes clear that agreements do not transfer away statutory or regulatory responsibilities. Apply the guidance according to the actual arrangement and jurisdiction, not as a generic certificate checklist. [2]

For day-to-day coordination, use an issue register: discrepancy, affected document, potential decision impact, assigned owner and agreed follow-up. Mark an issue closed only when the supporting explanation has been reviewed. An email saying “confirmed” may need a reference to the corrected record or assessment so that another reviewer can follow the reasoning later.

6. Close the review without overstating its conclusion

Summarize what was checked, what remains open and which decision the package supports. “Document identities reconciled for technical review” is a narrower conclusion than “supplier approved” or “shipment released.” Use the narrower wording when that is all the work establishes.

Retain the reviewed version set and avoid overwriting it with subsequent revisions without a record. Keep commercial timing separate from whether a technical issue has been adequately addressed. This makes the handover easier to audit and reduces the risk that different teams act on different document sets.

For a quality and documentation discussion, start with a non-confidential description of the decision and the missing evidence. Use the technical inquiry route to identify the appropriate next review. Specific records, supply roles and permitted uses must be confirmed for the project; this workflow does not establish unrestricted supply or finished-product authorization.